FGBweb_BFGBweb_BFGBweb_BFGBweb_B
  • THE FOUNDATION
    • About Us
    • Background
    • Our Mission
    • Contact Us
  • PROGRAMS
    • Fellowships
    • Research
  • NEWS & UPDATES
    • News
    • Press Area
  • VIDEO
English
  • Italiano
✕
Efficacy of nivolumab as neoadjuvant therapy in resectable lung cancer
11/07/2022
Durable clinical benefits in lung cancer with a KRASG12C inhibitor
25/07/2022

A novel antibody-drug conjugate for metastatic breast cancer patients

Published by Fondazione Gianni Bonadonna at 18/07/2022
Categories
  • Events
  • Uncategorized
Tags

    A phase I study shows a manageable safety profile with promising preliminary signs of activity of ARX788 in patients with HER2-positive metastatic breast cancer

    A phase I study recently published on Clinical Cancer Research shows safety and antitumor activity of ARX788, a novel antibody–drug conjugate, in patients with HER2-positive metastatic breast cancer.

    ARX788 is a novel antibody–drug conjugate comprised of an anti-HER2 monoclonal antibody and a potent tubulin inhibitor payload AS269 that is site-specifically conjugated to the antibody via a nonnatural amino acid incorporated into the antibody. Authors involved 69 patients with metastatic breast cancer who received ARX788 at different doses every 3 or 4 weeks. No dose-limiting toxicity or drug-related deaths occurred. Most patients experienced at least one treatment-related adverse event and the common ones (≥ 30%) included an increase in aspartate aminotransferase, an increase in alanine aminotransferase, corneal epitheliopathy, alopecia, hypokalemia, interstitial lung disease/pneumonitis and an increase in aldosterone; 34.8% of participants experienced interstitial lung disease/pneumonitis, but only 2 had a severity of grade 3. At 1.5 mg/kg every 3 weeks, the recommended phase II dose, the objective response rate was 65.5%, the disease control rate was 100%, and the median progression-free survival was 17 months. «These results showed that ARX788 had a manageable safety profile, circulating stability, and promising preliminary signs of clinical activity in HER2-positive metastatic breast cancer patients who progressed on prior anti-HER2 therapies. The non-cleavable linker rendered the antibody-drug conjugate highly stable in the circulation, resulting in relatively less payload-related off-target toxicity. A pivotal phase II/III randomized controlled, multicenter clinical trial is rapidly enrolling HER2-positive metastatic breast cancer patients to confirm these findings», authors conclude.

    Share
    0

    Related posts

    20/03/2023

    Dabrafenib and trametinib in anaplastic advanced thyroid cancer


    Read more
    13/03/2023

    Mediterranean diet could improve efficacy of immunotherapy in advanced melanoma


    Read more
    06/03/2023

    Olaparib in BRCA-mutated, HER-2 negative metastatic breast cancer


    Read more

    Follow us

    LinkedIn | Facebook | Twitter
    • Privacy policy
    • Cookie policy
    © 2021 - Fondazione Gianni Bonadonna
      English
      • Italiano
      • English